Research graph
References from Beyond variant detection: Mismatch repair gene alterations in plasma cell-free DNA from 1,226 glioma samples, and plasma-confirmed functional deficiency in an unbiopsied pontine glioma. Local targets link to admitted publications; unresolved targets remain external evidence.
Current opinion on molecular characterization for GBM classification in guiding clinical diagnosis, prognosis, and therapy
10.3389/fmolb.2020.562798 · 2020 · External reference
Molecular markers of gliomas to predict treatment and prognosis: current state and future directions
2021 · External reference
The 2021 WHO classification of Tumors of the Central Nervous System: a summary
10.1093/neuonc/noab106 · 2021 · External reference
Molecular biomarker testing for the diagnosis of diffuse gliomas
10.5858/arpa.2021-0295-cp · 2022 · External reference
Actionable alterations in glioblastoma: insights from the implementation of genomic profiling as the standard of care from 2016 to 2023
10.1093/nop/npae082 · 2025 · External reference
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
10.1126/science.aan6733 · 2017 · External reference
Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline Biallelic Mismatch repair deficiency
10.1200/jco.2016.66.6552 · 2016 · External reference
Mechanisms and therapeutic implications of hypermutation in gliomas
10.1038/s41586-020-2209-9 · 2020 · External reference
The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study
10.1016/s1470-2045(24)00640-5 · 2025 · External reference
Diffuse midline gliomas: challenges and new strategies in a changing clinical landscape
10.3390/cancers16010219 · 2024 · External reference
Liquid biopsy in glioblastoma
10.3390/cancers14143394 · 2022 · External reference
Tapping into the genome: the role of CSF ctDNA liquid biopsy in glioma
2022 · External reference
Clinical utility of plasma cell-free DNA in gliomas
2022 · External reference
Detection of circulating tumor DNA in early- and late-stage human malignancies
10.1126/scitranslmed.3007094 · 2014 · External reference
Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors
10.2217/cns-2018-0015 · 2019 · External reference
Circulating Tumor DNA in adults with glioma: a systematic review and meta-analysis of biomarker performance
10.1227/neu.0000000000001982 · 2022 · External reference
Detection of gene mutations and gene–gene fusions in circulating cell‐free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis
10.1002/1878-0261.13157 · 2022 · External reference
Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation
10.1016/j.prp.2024.155571 · 2024 · External reference
Beyond the blood: CSF-Derived cfDNA for diagnosis and characterization of CNS tumors
10.3389/fcell.2020.00045 · 2020 · External reference
Validation of microsatellite instability detection using a comprehensive plasma-based genotyping Panel
10.1158/1078-0432.ccr-19-1324 · 2019 · External reference
Clinically relevant and minimally invasive tumor surveillance of pediatric diffuse midline gliomas using patient-derived liquid biopsy
10.1158/1078-0432.ccr-18-1345 · 2018 · External reference
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data
10.1158/2159-8290.cd-12-0095 · 2012 · External reference
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
10.1016/s1470-2045(15)00088-1 · 2015 · External reference
Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT)
10.1016/j.jmoldx.2014.12.006 · 2015 · External reference
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
10.1038/nature07385 · 2008 · External reference
Analytical and clinical validation of a digital sequencing Panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA
10.1371/journal.pone.0140712 · 2015 · External reference
Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma: a pilot prospective Study
10.1158/1078-0432.ccr-19-2533 · 2020 · External reference
Liquid biopsy in glioblastoma: opportunities, applications and challenges
10.3390/cancers11070950 · 2019 · External reference
Evaluating cancer of the central nervous System through next-generation sequencing of cerebrospinal fluid
10.1200/jco.2016.66.6487 · 2016 · External reference
Tracking tumor evolution in glioma through liquid biopsies of cerebrospinal fluid
10.1038/s41586-019-0882-3 · 2019 · External reference
Current immunotherapeutic approaches to diffuse intrinsic pontine glioma
10.3389/fgene.2024.1349612 · 2024 · External reference
Immune microenvironment and immunotherapies for diffuse intrinsic pontine glioma
2023 · External reference
Ultra-low-input cell-free DNA sequencing for tumor detection and characterization in a real-world pediatric brain tumor cohort
10.1186/s40478-025-02024-w · 2025 · External reference
Pan-Cancer prevalence of Microsatellite instability-high (MSI-H) identified by circulating tumor DNA and associated real-world clinical outcomes
2023 · External reference
The current status of immune checkpoint inhibitors in pediatric CNS tumors: a systematic review with a representative case of CMMRD-associated glioma
10.1007/s11060-025-05241-4 · 2025 · External reference
Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis
10.1007/s00401-020-02243-6 · 2021 · External reference
Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA
10.1007/s00401-018-1936-6 · 2019 · External reference
Liquid biopsy of cerebrospinal fluid enables selective profiling of glioma molecular subtypes at first clinical presentation
10.1158/1078-0432.ccr-22-2903 · 2023 · External reference
Utilization of next generation sequencing from glioma patient liquid biopsy to determine survival prognostics: a systematic review
10.1016/j.gene.2026.150103 · 2026 · External reference
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment
10.1002/ijc.33481 · 2021 · External reference
